The urgent need to recover MHC class I in cancers for effective immunotherapy

Current Opinion in Immunology
Federico GarridoThorbald van Hall

Abstract

Immune escape strategies aimed to avoid T-cell recognition, including the loss of tumor MHC class I expression, are commonly found in malignant cells. Tumor immune escape has proven to have a negative effect on the clinical outcome of cancer immunotherapy, including treatment with antibodies blocking immune checkpoint molecules. Hence, there is an urgent need to develop novel approaches to overcome tumor immune evasion. MHC class I antigen presentation is often affected in human cancers and the capacity to induce upregulation of MHC class I cell surface expression is a critical step in the induction of tumor rejection. This review focuses on characterization of rejection, escape, and dormant profiles of tumors and its microenvironment with a special emphasis on the tumor MHC class I expression. We also discuss possible approaches to recover MHC class I expression on tumor cells harboring reversible/'soft' or irreversible/'hard' genetic lesions. Such MHC class I recovery approaches might well synergize with complementary forms of immunotherapy.

References

Aug 7, 1986·Nature·H Festenstein, F Garrido
Jan 10, 2001·International Journal of Cancer. Journal International Du Cancer·A Garcia-LoraF Garrido
Jul 8, 2003·International Journal of Cancer. Journal International Du Cancer·Angel Garcia-LoraFederico Garrido
Mar 22, 2006·Nature Medicine·Thorbald van HallRienk Offringa
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck PagèsJérôme Galon
Feb 24, 2010·International Journal of Cancer. Journal International Du Cancer·Federico GarridoNatalia Aptsiauri
Mar 4, 2010·International Journal of Cancer. Journal International Du Cancer·Matthias KloorMagnus von Knebel Doeberitz
Jan 11, 2011·Cancer Research·Véronique CorbièrePierre G Coulie
Feb 8, 2011·Current Opinion in Immunology·Margit H Lampen, Thorbald van Hall
May 10, 2011·Cancer Immunology, Immunotherapy : CII·Cristina GarridoFederico Garrido
Oct 4, 2011·International Journal of Cancer. Journal International Du Cancer·Rafael CarreteroTeresa Cabrera
Nov 26, 2011·Cancer Immunology, Immunotherapy : CII·Ursula J E SeidelThorbald van Hall
Nov 29, 2011·Cancer Immunology, Immunotherapy : CII·Barbara Seliger
Feb 9, 2012·Tissue Antigens·A B del CampoF Garrido
Feb 22, 2012·Cell·Elizabeth P MurchisonMichael R Stratton
Jul 11, 2012·Advances in Urology·Eric J AskelandYi Luo
Jul 27, 2012·Cancer Immunology, Immunotherapy : CII·Monica BernalFederico Garrido
Nov 28, 2012·Molecular Immunology·Claudia C Oliveira, Thorbald van Hall
Dec 5, 2012·The Journal of Experimental Medicine·Jing NiAdelheid Cerwenka
Apr 18, 2013·Cancer Research·Sylvie RusakiewiczLaurence Zitvogel
Jun 21, 2013·International Journal of Cancer. Journal International Du Cancer·Ana B del CampoNatalia Aptsiauri
Feb 18, 2014·Cancer Research·Irene RomeroAngel M Garcia-Lora
Mar 4, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lidia RobertAntoni Ribas
Jul 30, 2014·Proceedings of the National Academy of Sciences of the United States of America·KiBem KimShibin Zhou
Oct 21, 2014·The Journal of Clinical Investigation·Michele ArdolinoDavid H Raulet
Nov 21, 2014·Cancer Research·Irene RomeroAngel M Garcia-Lora
Dec 5, 2014·International Journal of Cancer. Journal International Du Cancer·Federico GarridoAngel M Garcia-Lora
Jun 23, 2015·Frontiers in Immunology·Cláudia C Oliveira, Thorbald van Hall
Jan 20, 2016·The Journal of Clinical Investigation·Elien M DoorduijnThorbald van Hall

❮ Previous
Next ❯

Citations

Jun 18, 2016·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Marie KostineJudith V M G Bovée
Sep 7, 2016·Vaccines·Saskia J A M SantegoetsSjoerd H van der Burg
Oct 19, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Marie de CharetteRoch Houot
Oct 28, 2016·International Journal of Cancer. Journal International Du Cancer·Francisco PereaFrancisco Ruiz-Cabello
Mar 9, 2018·Expert Opinion on Therapeutic Targets·Ariel Fernández
Jun 22, 2017·International Journal of Molecular Sciences·Michal Šmahel
Oct 13, 2017·European Journal of Immunology·Andrea CossarizzaJakob Zimmermann
Mar 31, 2018·Cancer Immunology, Immunotherapy : CII·Daniel Rojas-SepúlvedaFlavio Salazar-Onfray
Feb 3, 2018·Annual Review of Immunology·Peter Parham, Lisbeth A Guethlein
Jul 21, 2016·Journal for Immunotherapy of Cancer·Sonia T Chelbi, Greta Guarda
Apr 11, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Dana A Emerson, William L Redmond
Aug 25, 2017·Future Oncology·Marc S ErnstoffCarl Morrison
Oct 5, 2017·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Joan M C Bull
Aug 23, 2018·The Journal of Experimental Medicine·Mathieu Gigoux, Jedd Wolchok
Nov 27, 2018·ILAR Journal·Nana H OvergaardGregers Jungersen
Jan 23, 2019·Advanced Healthcare Materials·Eun Sook LeeJae Hyung Park
Feb 16, 2019·Omics : a Journal of Integrative Biology·Shankargouda PatilMarco Ferrari
Feb 13, 2019·The Journal of Clinical Investigation·Tina GruossoMorag Park
May 18, 2019·Metallomics : Integrated Biometal Science·Martina RaudenskaMichal Masarik
May 1, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Vid LekoYong-Chen Lu
Jun 22, 2017·EMBO Molecular Medicine·Joshua D FreedmanLeonard W Seymour
Sep 12, 2019·Immunology·Federico Garrido, Natalia Aptsiauri
Apr 21, 2016·Journal for Immunotherapy of Cancer·Per Thor Straten, Federico Garrido
Jan 12, 2020·Molecular Biology Reports·Feng TangBing Zhao
Mar 19, 2020·Cancers·Elżbieta ChruścielNatalia Marek-Trzonkowska
Apr 2, 2020·Expert Opinion on Therapeutic Targets·Christopher LarsonTony R Reid
Sep 6, 2019·Virchows Archiv : an International Journal of Pathology·Anjelica HodgsonMichelle R Downes
Mar 27, 2020·Journal for Immunotherapy of Cancer·Lorenzo GalluzziFrancesco M Marincola
Oct 6, 2017·Oncotarget·Helen H W Chen, Macus Tien Kuo

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
transgenic

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Related Papers

Current Opinion in Immunology
Margit H Lampen, Thorbald van Hall
Cancer Immunology, Immunotherapy : CII
Chien-Chung Chang, Soldano Ferrone
The Journal of Immunology : Official Journal of the American Association of Immunologists
Jason L PetersenJoyce C Solheim
© 2022 Meta ULC. All rights reserved